Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects

Exclusion Criteria

• •History of cancer or clinically significant lymphoproliferative disease with fewer than 5 years documented disease-free state
• •Participation in clinical study within 30 days for drug or 90 days for antibody
• •Use of native GLP-2 or human growth hormone (HGH) within 6 months of screening
• •Use of iv glutamine within 30 days prior to screening
• •Use of teduglutide
• •CD patients who have been treated with biological therapy within 6 months of screening
• •IBD patients who require chronic systemic immunosuppressant therapy
• •More than 4 SBS- or PN-related hospitalizations within 12 months of screening
• •Unplanned hospitalization within one month of screening
• •Pregnant or lactating women
• •Body weight \> 88kg
• •Body mass index (BMI) \< 15 kg/m2
• •Severe hepatic impairment or disturbed renal function
• •Female subjects who are not surgically sterile or postmenopausal or who are not using medically acceptable methods of birth control during and for 30 days after the treatment period
• •Not capable of understanding or not willing to adhere to the study visit schedules and other protocol requirements
• •Any condition or circumstance that is the investigator's opinion would put the subject at any undue risk, prevent completion of the study, or interfere with the analysis of the study results
• •Significant active, uncontrolled, untreated systemic diseases